Biofrontera Inc (BFRI)

Currency in USD
1.5200
-0.0100(-0.65%)
Real-time Data·
BFRI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.52001.5500
52 wk Range
0.55471.6100
Key Statistics
Prev. Close
1.53
Open
1.54
Day's Range
1.52-1.55
52 wk Range
0.5547-1.61
Volume
45.92K
Average Volume (3m)
413.52K
1-Year Change
71.5382%
Book Value / Share
0.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BFRI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.0000
Upside
+294.74%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low revenue valuation multiple

Biofrontera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.0000
(+294.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Benchmark
Buy3.00+96.08%-Downgrade19-05-2026
Benchmark
Buy3.00+96.08%3.00Maintain14-11-2025
Benchmark
Buy3.00+96.08%3.00Maintain03-10-2025

Biofrontera Inc Earnings Call Summary for Q2/2026

  • Biofrontera Q2 2026 revenue hit $12.0M vs. $10.5M forecast, up 32.9% YoY; net loss $0.05/share beat est. $0.14 loss; shares surged 9.6% to $1.37.
  • Gross margin expanded to 80% from 71% YoY on new cost structure; adjusted EBITDA loss narrowed to $0.2M from $5.1M; company called it strongest Q2 ever.
  • FDA set Sept. 28, 2026 action date for Ameluz sBCC approval, first PDT for cancerous skin tumors; full launch expected Q1 2027 following Q4 2026 outreach.
  • Company plans Q3 2026 filing for actinic keratosis label expansion with expected Q3 2027 approval; maintains full-year 2026 revenue guidance despite ITC ruling.
  • Cash position of $4.7M raises liquidity concerns amid ongoing burn; CFO targets 2026 breakeven via revenue growth, $1M milestone payment, potential credit facility.
Last Updated: 13-08-2026, 08:40 pm
Read Full Transcript

Earnings

Latest Release
13-08-2026
EPS / Forecast
-0.05 / -0.14
Revenue / Forecast
12M / 10.5M
EPS Revisions
Last 90 days

BFRI Income Statement

Compare BFRI to Peers and Sector

Metrics to compare
BFRI
Peers
Sector
Relationship
P/E Ratio
−3.6x−1.7x−0.4x
PEG Ratio
−0.050.010.00
Price/Book
3.8x1.9x2.6x
Price / LTM Sales
0.5x2.6x3.1x
Upside (Analyst Target)
292.2%404.1%49.4%
Fair Value Upside
Unlock0.0%6.8%Unlock

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Employees
89

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
218.07K1.47%333.65K
Other Institutional Investors
5.21M35.06%7.97M
Public Companies & Retail Investors
9.43M63.47%14.42M
Total
14.85M100.00%22.72M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Rosalind Master Fund L.P.8.59%12,75,6091,952
Rosalind Advisors, Inc.8.59%12,75,6091,952

FAQ

What Is the Biofrontera (BFRI) Share Price Today?

The Biofrontera share price today is 1.5200.

What is the current Biofrontera (BFRI) share price and day range?

As of 01-09-2026, the Biofrontera share price is 1.5200, with a previous close of 1.5300. The share price has ranged from 1.5200 to 1.5500 today, while the 52-week range spans from 0.5547 to 1.6100.

What Is the Biofrontera Market Cap?

As of today, Biofrontera market cap is 22.7200M.

What Is the Biofrontera (BFRI) Share Price Target?

The average 12-month share price target for Biofrontera is 6.0000, with a high estimate of 9 and a low estimate of 3. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +294.74% Upside potential.

What Is Biofrontera's Earnings Per Share (TTM)?

The Biofrontera EPS (TTM) is -0.5407.

When Is the Next Biofrontera Earnings Date?

Biofrontera will release its next earnings report on 18-11-2026.

From a Technical Analysis Perspective, Is BFRI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Biofrontera Trade On?

Biofrontera is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Biofrontera?

The stock symbol for Biofrontera is "BFRI."

How Many Times Has Biofrontera Stock Split?

Biofrontera has split 1 times.

How Many Employees Does Biofrontera Have?

Biofrontera has 89 employees.

What Is the BFRI Premarket Price?

BFRI's last pre-market stock price is 1.5304. The pre-market share volume is 8,230.0000, and the stock has changed by 0.0004, or 0.0300%.

What Is the BFRI After Hours Price?

BFRI's last after hours stock price is 1.5700, the stock has changed by 0.0400, or 2.6100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.